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X V I 
III. 1.1 Hyperthyroid heart disease: 
Diagnostic and therapeutic aspects 
P C. Scriba 
The secondary cardiopathy following an abnormality of the thyroid gland 
function may be accessable to causal treatment. This is one of the reasons for 
the cardiologists interest in endocrinology. The cardiovascular changes to be 
observed in thyrotoxicosis may be clearer in perspective when dealt with in 
comparison to hypothyroidism. For this reason, a case of myxedematous 
heart disease is demonstrated first. 
The condition of myxedematous heart disease was first described and 
named by Hermann Zondek. Zondek had to leave our country in the early 
30s and died 1979 in Jerusalem [1], Prof. Zondek was one of the outstanding 
endocrinologists who as a victim of German policy and crime disappeared 
from Berlin and left the country so much poorer. In these days, we shall 
commemorate in this country the 50th anniversary of a day of terror and 
shame, the Reichskristallnacht. Remembering H . Zondek may add to our 
awareness of the past and help in aiming at a better world. 
A brief description of the heart in hypothyroidism should Start with the 
fact, that myocardial function is itself altered in the sence of a diminished 
function. Vora et al. [2] were able to demonstrate a slowed diastolic thinning 
rate of the posterior ventricular wall. - Further, the prolonged systolic time 
interval may be used as peripheral sign of hypothyroidism [3]. - The reader is 
referred to recent reviews for further details [3, 4]. It is well known, that 
hypothyroid patients tolerate less digoxin than euthyroid patients. The re-
verse is true for hyperthyroid patients. Giving a constant dose of 0.25 mg 
digoxin or 0.1 mg digitoxin, respectively, resulted in lower serum levels of 
digoxin in thyrotoxic patients as compared to euthyroid and hypothyroid 
patients, respectively [5]. The levels were negatively correlated to Creatinine 
clearance, the latter obviously contributing to what is known as refractoriness 
to digitalis in hyperthyroidism. Notably, the levels for digitoxin were not 
different under these conditions. 
A systematic comparison of the changes of the heart in thyrotoxicosis and 
hypothyroidism [3] has to list among others the two most prominent aspects 
of 1. cardiac failure and 2. arrhythmia in thyrotoxicosis. 
Congestive heart failure and cardiac hypertrophy are sometimes though 
certainly not regularily observed in thyrotoxic patients as demonstrated in 2 
such cases. Dr. Dillmann has dealt with the direct effect of thyroxine on the 
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myocardium. Forfar et al. [6] were able to show, that the left ventricular 
ejection fraction was decreased in thyrotoxic patients by exercise, whereas it 
increases in controls. This and the ratio of the ejection time to L V E T were 
not normalized by Propranolol. The latter Observation was used as an argu-
ment for the direct effect of thyroxine. 
In addition, there is evidence in the literatur [7] that a prolaps of the mitral 
valve may be observed in approximately half of the patients with im-
munogenic hyperthyroidism but only in 2 of 20 patients with thyrotoxicosis 
due to thyroidal autonomy. Further, the prolaps of the mitral valve was 
correlated to endocrine orbitopathy rather than to actual thyrotoxicosis. A 
"myxedematous" State of the mitral valve specific for immunogenic hyper-
thyroidism was therefore claimed [7]. 
Absolute arrhythmia due to atrial flutter or fibrillation may be observed in 
10-15% of all thyrotoxic patients [3, 4]. When euthyroidism is achieved, 
some 60-90% of these patients return to normal sinus rhythm spontaneously. 
If medical or electrical cardioversion has to be applied at all, this should be 
done only after the patient has been euthyroid for a few months. 
Regarding this problem the other way round, some 6-10% of all patients 
with absolute arrhythmia are reported to have thyrotoxicosis. Interestingly, 
Forfar et al. [8] have studied 4 patients who actually had only a negative T R H 
test but no T 4 or T 3 elevation and could only be converted after antithyroid 
treatment. - The explanation of arrhythmia in thyrotoxic patients is complex. 
Direct thyroxine effects and an increased sensitivity towards catecholamines 
play their role. Some of the patients probably have preexistent and contribut-
ing coronary heart disease. This may be concluded from occasional E C G 
changes of the ischemic type which disappeared after antithyroid treatment 
as observed in some of our patients. A n increase in supraventricular extrasys-
tolies may trigger atrial fibrillation. 
Finally, the well known effectiveness of blocking beta-receptors in thy-
rotoxic patients has to be mentioned. A word of caution may be added. Beta-
receptor blocking may be unnecessary and probably even dangerous if given 
too long and bradycardia should be carefully avoided in the thyrotoxic 
patient. 
In summary, this short overview was meant as a clinical introduction to the 
review by W. H . Dillmann. 
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